Psoriasis - Epidemiology Forecast - 2034
Description
Key Highlights
Psoriasis is a chronic (long-lasting) disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. Patches of skin become scaly and inflamed, most often on the scalp, elbows, or knees, but other parts of the body can be affected as well.
The total number of diagnosed prevalent cases in the 7MM ranges from 15,887,600 in 2024.
Epidemiology assessed for psoriasis showed that the US, in 2024, accounted for approximately 50% of diagnosed prevalent cases of psoriasis.
In the EU4 and the UK, Germany had the highest number of diagnosed cases of psoriasis (28%), while Spain accounted for the lowest number (14%) of diagnosed prevalent cases.
Japan accounted for 490,800 cases of mild psoriasis in 2024.
Among the type-specific cases of psoriasis, erythrodermic psoriasis accounted for the least number of cases in the 7MM.
In Japan, approximately 86% of psoriasis cases were mild, while the remaining 14% from moderate to severe in 2020.
DelveInsight’s ‘Psoriasis – Epidemiology – 2034’ report delivers an in-depth understanding of the psoriasis, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Psoriasis Understanding
Psoriasis Overview
Psoriasis is a chronic (long-lasting) disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. Patches of skin become scaly and inflamed, most often on the scalp, elbows, or knees, but other parts of the body can be affected as well.
The symptoms of psoriasis can sometimes go through cycles, flaring for a few weeks or months, followed by periods when they subside or go into remission. There are many ways to treat psoriasis, and your treatment plan will depend on the type and severity of the disease. Clinical manifestations of chronic pancreatitis include recurrent severe abdominal pain, weight loss, steatorrhea, diabetes mellitus, nausea, vomiting, bloating, indigestion, and changes in bowel habits. Complications such as pseudocysts, pancreatic duct strictures, bile duct obstruction, and pancreatic cancer may also occur.
Psoriasis is a chronic, immune-mediated disease resulting from the overproduction of skin cells accumulating on the skin’s surface, which causes red, scaly plaques that may itch and bleed.
Psoriasis Diagnosis
Dermatologists can identify psoriasis lesions and diagnose the condition during a physical exam. Occasionally, the doctor may recommend a biopsy to remove a small amount of skin for laboratory testing to distinguish psoriasis from another cause of a rash, such as eczema.
Physical examination
A dermatologist examines the skin and notes the location, distribution, size, shape, and appearance of lesions. During a physical exam, they may also enquire about symptoms and medical history, including whether someone else in the family has been diagnosed with psoriasis.
Skin biopsy
A biopsy is a test in which a pathologist examines skin cells under a microscope to determine whether psoriasis is the cause of symptoms. Dermatologists usually perform a punch biopsy. The “punch” name describes the technique: The doctor uses a device the size and shape of a pencil to puncture the skin and remove a small tissue sample.
Differential Diagnosis
Several differential diagnoses could be considered with other inflammatory, infectious, and/or neoplastic disorders. Topographical differential diagnosis may include seborrheic dermatitis, tinea capitis, lichen planopilaris in the scalp; lupus erythematosus, dermatomyositis, cutaneous T-cell lymphomas, atopic dermatitis, syphilis, tinea corporis, pityriasis rubra pilaris in the trunk and arms; infectious intertrigo in the inguinal and intergluteal folds and eczema and palmoplantar keratoderma in the palms and soles.
Possible Directions in the Diagnosis of Psoriasis
Although histopathology remains the undisputed gold standard diagnostic test for psoriasis, it is an invasive procedure. Therefore, further efforts are warranted to substantiate the clinical diagnosis non-invasively.
Dermoscopy: Dermoscopy, also known as dermatoscopy or epiluminescence microscopy, is a non-invasive imaging technique that allows dermatologists to examine the skin at a magnified level, revealing features that may not be visible to the naked eye.
Optical Coherence Tomography (OCT) has emerged as a valuable imaging technique in evaluating and managing psoriasis. OCT is a noninvasive imaging method that provides high-resolution, cross-sectional images of the skin in real-time.
Ultrasound: Psoriatic plaques are characterized by skin thickening due to increased cell turnover. Ultrasound is a valuable tool for measuring skin layer thickness and providing quantitative data to monitor disease severity and treatment response.
Reflectance Confocal Microscopy (RCM) can be used to assess structural and cellular changes characteristic of psoriatic lesions, providing detailed information on inflammation, vascularization, and cell proliferation.
Further details are provided in the report.
Psoriasis Epidemiology
As the market is derived using a patient-based model, the psoriasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented total diagnosed prevalence cases of psoriasis in the 7MM, type-specific diagnosed prevalence cases of psoriasis in the 7MM, location-specific diagnosed prevalence cases of psoriasis in the 7MM, severity-specific diagnosed prevalence cases of psoriasis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The total number of diagnosed prevalent cases in the 7MM ranges from 15,887,600 in 2024.
Among the location-specific contributions, scalp psoriasis had the highest occurrence of cases from 4,811,200 in 2024 in the US.
Among EU4 countries, Germany accounted for the maximum number of psoriasis cases, followed by the UK, whereas Spain accounted for the minimum cases, in 2024.
In the UK, the highest number of type-specific diagnosed prevalent cases of plaque psoriasis, totaling 1,262,300 cases in 2024.
Psoriasis is predominantly observed in adults, accounting for approximately 97% of all cases in the 7MM in 2024.
In 2024. Japan accounts for 3% of the total number of diagnosed prevalent cases of psoriasis.
Psoriasis Report Insights
Patient population
Country-wise epidemiology distribution
Psoriasis Report Key Strengths
Ten-year forecast
7MM coverage
Psoriasis epidemiology segmentation
Psoriasis Disease Report Assessment
Unmet Needs
Current Diagnostic Practices
FAQs
What are psoriasis disease risks, burdens, and unmet needs? What will be the growth opportunities across the 7MM concerning the patient population with psoriasis?
What is the historical and forecasted psoriasis patient pool in the US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan?
At what CAGR is the population expected to grow in the 7MM during the study period (2020–2034)?
What will be the growth opportunities in the 7MM with respect to the patient population of psoriasis?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Psoriasis is a chronic (long-lasting) disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. Patches of skin become scaly and inflamed, most often on the scalp, elbows, or knees, but other parts of the body can be affected as well.
The total number of diagnosed prevalent cases in the 7MM ranges from 15,887,600 in 2024.
Epidemiology assessed for psoriasis showed that the US, in 2024, accounted for approximately 50% of diagnosed prevalent cases of psoriasis.
In the EU4 and the UK, Germany had the highest number of diagnosed cases of psoriasis (28%), while Spain accounted for the lowest number (14%) of diagnosed prevalent cases.
Japan accounted for 490,800 cases of mild psoriasis in 2024.
Among the type-specific cases of psoriasis, erythrodermic psoriasis accounted for the least number of cases in the 7MM.
In Japan, approximately 86% of psoriasis cases were mild, while the remaining 14% from moderate to severe in 2020.
DelveInsight’s ‘Psoriasis – Epidemiology – 2034’ report delivers an in-depth understanding of the psoriasis, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Psoriasis Understanding
Psoriasis Overview
Psoriasis is a chronic (long-lasting) disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. Patches of skin become scaly and inflamed, most often on the scalp, elbows, or knees, but other parts of the body can be affected as well.
The symptoms of psoriasis can sometimes go through cycles, flaring for a few weeks or months, followed by periods when they subside or go into remission. There are many ways to treat psoriasis, and your treatment plan will depend on the type and severity of the disease. Clinical manifestations of chronic pancreatitis include recurrent severe abdominal pain, weight loss, steatorrhea, diabetes mellitus, nausea, vomiting, bloating, indigestion, and changes in bowel habits. Complications such as pseudocysts, pancreatic duct strictures, bile duct obstruction, and pancreatic cancer may also occur.
Psoriasis is a chronic, immune-mediated disease resulting from the overproduction of skin cells accumulating on the skin’s surface, which causes red, scaly plaques that may itch and bleed.
Psoriasis Diagnosis
Dermatologists can identify psoriasis lesions and diagnose the condition during a physical exam. Occasionally, the doctor may recommend a biopsy to remove a small amount of skin for laboratory testing to distinguish psoriasis from another cause of a rash, such as eczema.
Physical examination
A dermatologist examines the skin and notes the location, distribution, size, shape, and appearance of lesions. During a physical exam, they may also enquire about symptoms and medical history, including whether someone else in the family has been diagnosed with psoriasis.
Skin biopsy
A biopsy is a test in which a pathologist examines skin cells under a microscope to determine whether psoriasis is the cause of symptoms. Dermatologists usually perform a punch biopsy. The “punch” name describes the technique: The doctor uses a device the size and shape of a pencil to puncture the skin and remove a small tissue sample.
Differential Diagnosis
Several differential diagnoses could be considered with other inflammatory, infectious, and/or neoplastic disorders. Topographical differential diagnosis may include seborrheic dermatitis, tinea capitis, lichen planopilaris in the scalp; lupus erythematosus, dermatomyositis, cutaneous T-cell lymphomas, atopic dermatitis, syphilis, tinea corporis, pityriasis rubra pilaris in the trunk and arms; infectious intertrigo in the inguinal and intergluteal folds and eczema and palmoplantar keratoderma in the palms and soles.
Possible Directions in the Diagnosis of Psoriasis
Although histopathology remains the undisputed gold standard diagnostic test for psoriasis, it is an invasive procedure. Therefore, further efforts are warranted to substantiate the clinical diagnosis non-invasively.
Dermoscopy: Dermoscopy, also known as dermatoscopy or epiluminescence microscopy, is a non-invasive imaging technique that allows dermatologists to examine the skin at a magnified level, revealing features that may not be visible to the naked eye.
Optical Coherence Tomography (OCT) has emerged as a valuable imaging technique in evaluating and managing psoriasis. OCT is a noninvasive imaging method that provides high-resolution, cross-sectional images of the skin in real-time.
Ultrasound: Psoriatic plaques are characterized by skin thickening due to increased cell turnover. Ultrasound is a valuable tool for measuring skin layer thickness and providing quantitative data to monitor disease severity and treatment response.
Reflectance Confocal Microscopy (RCM) can be used to assess structural and cellular changes characteristic of psoriatic lesions, providing detailed information on inflammation, vascularization, and cell proliferation.
Further details are provided in the report.
Psoriasis Epidemiology
As the market is derived using a patient-based model, the psoriasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented total diagnosed prevalence cases of psoriasis in the 7MM, type-specific diagnosed prevalence cases of psoriasis in the 7MM, location-specific diagnosed prevalence cases of psoriasis in the 7MM, severity-specific diagnosed prevalence cases of psoriasis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The total number of diagnosed prevalent cases in the 7MM ranges from 15,887,600 in 2024.
Among the location-specific contributions, scalp psoriasis had the highest occurrence of cases from 4,811,200 in 2024 in the US.
Among EU4 countries, Germany accounted for the maximum number of psoriasis cases, followed by the UK, whereas Spain accounted for the minimum cases, in 2024.
In the UK, the highest number of type-specific diagnosed prevalent cases of plaque psoriasis, totaling 1,262,300 cases in 2024.
Psoriasis is predominantly observed in adults, accounting for approximately 97% of all cases in the 7MM in 2024.
In 2024. Japan accounts for 3% of the total number of diagnosed prevalent cases of psoriasis.
Psoriasis Report Insights
Patient population
Country-wise epidemiology distribution
Psoriasis Report Key Strengths
Ten-year forecast
7MM coverage
Psoriasis epidemiology segmentation
Psoriasis Disease Report Assessment
Unmet Needs
Current Diagnostic Practices
FAQs
What are psoriasis disease risks, burdens, and unmet needs? What will be the growth opportunities across the 7MM concerning the patient population with psoriasis?
What is the historical and forecasted psoriasis patient pool in the US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan?
At what CAGR is the population expected to grow in the 7MM during the study period (2020–2034)?
What will be the growth opportunities in the 7MM with respect to the patient population of psoriasis?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
165 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary
- 4. Epidemiology and Market Forecast Methodology
- 5. Psoriasis Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution of Psoriasis in 2020
- 5.2. Patient Share (%) Distribution of Psoriasis in 2034
- 6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Causes and Risk Factors
- 6.3. Types of Psoriasis
- 6.4. Pathophysiology
- 6.5. Diagnosis
- 6.5.1. Diagnostic Algorithm
- 6.5.2. Diagnostic Guidelines
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale: 7MM
- 7.3. The United States
- 7.3.1. Total Diagnosed Prevalent Cases of Psoriasis in the United States (2020–2034)
- 7.3.2. Type-specific Diagnosed Prevalent Cases of Psoriasis in the United States (2020–2034)
- 7.3.3. Location-specific Diagnosed Prevalent Cases of Psoriasis in the United States (2020–2034)
- 7.3.4. Severity-specific Diagnosed Prevalent Cases of Psoriasis in the United States (2020–2034)
- 7.4. EU4 and the UK
- 7.4.1. Total Diagnosed Prevalent Cases of Psoriasis in EU4 and the UK (2020–2034)
- 7.4.2. Type-specific Diagnosed Prevalent Cases of Psoriasis in EU4 and the UK (2020–2034)
- 7.4.3. Location-specific Diagnosed Prevalent Cases of Psoriasis in EU4 and the UK (2020–2034)
- 7.4.4. Severity-specific Diagnosed Prevalent Cases of Psoriasis in EU4 and the UK (2020–2034)
- 7.5. Japan
- 7.5.1. Total Diagnosed Prevalent Cases of Psoriasis in Japan (2020–2034)
- 7.5.2. Type-specific Diagnosed Prevalent Cases of Psoriasis in Japan (2020–2034)
- 7.5.3. Location-specific Diagnosed Prevalent Cases of Psoriasis in Japan (2020–2034)
- 7.5.4. Severity-specific Diagnosed Prevalent Cases of Psoriasis in Japan (2020–2034)
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
